Gary Dubin

Overview

Best Publications

• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

  Diane M. Harper;Eduardo L. Franco;Cosette Wheeler;Daron Gale Ferris

  2367
  Citations

• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler

  2329
  Citations

• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

  Diane M Harper;Eduardo L Franco;Cosette M Wheeler;Anna-Barbara Moscicki

  2212
  Citations

• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

  Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud

  1955
  Citations

• Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

  Lawrence R. Stanberry;Spotswood L. Spruance;Anthony L. Cunningham;David I. Bernstein

  991
  Citations

• Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

  Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn

  935
  Citations

• ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

  J. Abramson;L. Pickering;Janet Gilsdorf

  888
  Citations

• Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

  Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

  838
  Citations

• Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

  Sandra L Giannini;Emmanuel Hanon;Philippe Moris;Marcelle Van Mechelen

  731
  Citations

• Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

  Cosette M. Wheeler;Xavier Castellsagué;Suzanne M. Garland;Anne Szarewski

  678
  Citations

• Efficacy Results of a Trial of a Herpes Simplex Vaccine

  Robert B. Belshe;Peter A. Leone;David I. Bernstein;Anna Wald

  593
  Citations

• Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

  Mark H. Einstein;Mira Baron;Myron J. Levin;Archana Chatterjee

  578
  Citations

• Serum antibody responses after intradermal vaccination against influenza.

  Robert B. Belshe;Frances K. Newman;Joan Cannon;Carol Duane

  487
  Citations

• Epidemiology, clinical presentation and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women

  David I. Bernstein;Abbie R. Bellamy;Edward W. Hook;Myron J. Levin

  394
  Citations

• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial

  Diane M. Harper;Eduardo L. Franco;Cosette Wheeler;Daron G. Ferris

  387
  Citations

• Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

  Romanowski B;de Borba Pc;Naud Ps

  366
  Citations

• Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

  Aimée R Kreimer;Frank Struyf;Maria Rowena Del Rosario-Raymundo;Allan Hildesheim

  346
  Citations

• Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

  Court Pedersen;Tiina Petaja;Gitte Strauss;Hans C. Rumke

  344
  Citations

• Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.

  Dominique Descamps;Karin Hardt;Bart Spiessens;Patricia Izurieta

  244
  Citations

• Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

  S. Rachel Skinner;S. Rachel Skinner;Anne Szarewski;Barbara Romanowski;Suzanne M. Garland

  237
  Citations

• Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection

  Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

  24
  Citations